These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 25572478)

  • 21. Diffuse large B-cell lymphoma.
    Martelli M; Ferreri AJ; Agostinelli C; Di Rocco A; Pfreundschuh M; Pileri SA
    Crit Rev Oncol Hematol; 2013 Aug; 87(2):146-71. PubMed ID: 23375551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoclonal antibodies in lymphoma: the first decade.
    Link BK; Friedberg JW
    Semin Hematol; 2008 Apr; 45(2):71-4. PubMed ID: 18381100
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of rituximab-resistant B-NHL clones: an in vitro model for studying tumor resistance to monoclonal antibody-mediated immunotherapy.
    Jazirehi AR; Bonavida B
    Methods Mol Biol; 2011; 731():407-19. PubMed ID: 21516425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New targeted therapies for malignant lymphoma based on molecular heterogeneity.
    Horn H; Staiger AM; Ott G
    Expert Rev Hematol; 2017 Jan; 10(1):39-51. PubMed ID: 27918211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diffuse large B-cell lymphoma of the orbit: clinicopathologic, immunohistochemical, and prognostic features of 20 cases.
    Stacy RC; Jakobiec FA; Herwig MC; Schoenfield L; Singh A; Grossniklaus HE
    Am J Ophthalmol; 2012 Jul; 154(1):87-98.e1. PubMed ID: 22503694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma.
    Bohers E; Mareschal S; Bouzelfen A; Marchand V; Ruminy P; Maingonnat C; Ménard AL; Etancelin P; Bertrand P; Dubois S; Alcantara M; Bastard C; Tilly H; Jardin F
    Genes Chromosomes Cancer; 2014 Feb; 53(2):144-53. PubMed ID: 24327543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan.
    Tanaka T; Shimada K; Yamamoto K; Hirooka Y; Niwa Y; Sugiura I; Kitamura K; Kosugi H; Kinoshita T; Goto H; Nakamura S
    Ann Hematol; 2012 Mar; 91(3):383-90. PubMed ID: 21822617
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual effect of DLBCL-derived EXOs in lymphoma to improve DC vaccine efficacy in vitro while favor tumorgenesis in vivo.
    Chen Z; You L; Wang L; Huang X; Liu H; Wei JY; Zhu L; Qian W
    J Exp Clin Cancer Res; 2018 Aug; 37(1):190. PubMed ID: 30103789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD4(+) tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy.
    Keane C; Gill D; Vari F; Cross D; Griffiths L; Gandhi M
    Am J Hematol; 2013 Apr; 88(4):273-6. PubMed ID: 23460351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging therapies for B-cell non-Hodgkin lymphoma.
    Briones J
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1305-16. PubMed ID: 19761434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ocular adnexal diffuse large B-cell lymphoma: local disease correlates with better outcomes.
    Madge SN; McCormick A; Patel I; Hatef E; Menon V; Prabhakaran VC; Irion L; Bonshek R; Honovar S; Leatherbarrow B; Esmaeli B; Selva D
    Eye (Lond); 2010 Jun; 24(6):954-61. PubMed ID: 19942938
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
    Jazirehi AR; Bonavida B
    Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells.
    Wang Y; Zhang WY; Han QW; Liu Y; Dai HR; Guo YL; Bo J; Fan H; Zhang Y; Zhang YJ; Chen MX; Feng KC; Wang QS; Fu XB; Han WD
    Clin Immunol; 2014 Dec; 155(2):160-75. PubMed ID: 25444722
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging drugs for diffuse large B-cell lymphoma.
    Mondello P; Younes A
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):439-51. PubMed ID: 25652253
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rituximab for the treatment of diffuse large B-cell lymphomas.
    Held G; Pöschel V; Pfreundschuh M
    Expert Rev Anticancer Ther; 2006 Aug; 6(8):1175-86. PubMed ID: 16925484
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab.
    Bittenbring JT; Neumann F; Altmann B; Achenbach M; Reichrath J; Ziepert M; Geisel J; Regitz E; Held G; Pfreundschuh M
    J Clin Oncol; 2014 Oct; 32(29):3242-8. PubMed ID: 25135997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of Aggressive B Cell Lymphomas: Updates in 2019.
    Mondello P; Nowakowski GS
    Curr Hematol Malig Rep; 2020 Jun; 15(3):225-234. PubMed ID: 32372238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical outcome in diffuse large B-cell lymphoma with hepatitis C virus infection in the rituximab era: a single center experience.
    Nishikawa H; Tsudo M; Osaki Y
    Oncol Rep; 2012 Sep; 28(3):835-40. PubMed ID: 22736295
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improving outcomes for patients with diffuse large B-cell lymphoma.
    Flowers CR; Sinha R; Vose JM
    CA Cancer J Clin; 2010; 60(6):393-408. PubMed ID: 21030533
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.
    Maeshima AM; Taniguchi H; Fukuhara S; Morikawa N; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
    Am J Surg Pathol; 2013 Apr; 37(4):563-70. PubMed ID: 23426122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.